<PAGE>
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 9, 2000
-------------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
-------------------------
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
PAGE 1 OF 4 PAGES.
<PAGE>
Item 5. OTHER EVENTS
On June 7, 2000, Genome Therapeutics Corp. issued a press release
announcing that the Company has secured rights to obtain worldwide exclusive
access to certain patented Single Nucleotide Polymorphisms (SNPs) detection
technology from Northeastern University. A copy of this press release is
attached to this Current Report on Form 8-K as Exhibit 99.1.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Philip V. Holberton
---------------------------
Name: Philip V. Holberton
Title: Chief Financial Officer
Date: June 9, 2000
<PAGE>
EXHIBIT INDEX
-------------
99.1 Press Release dated June 7, 2000
